Literature DB >> 17652963

Signaling axis in osteoclast biology and therapeutic targeting in the RANKL/RANK/OPG system.

Sakae Tanaka1.   

Abstract

Bone integrity is maintained through a balance between bone formation and bone resorption, and osteoclasts are primary cells involved in bone resorption. Recent studies have revealed an essential role of macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa-B ligand (RANKL) in the development of osteoclasts, and detailed molecular cascades that induce osteoclast differentiation, activation and apoptosis have been clarified. Osteoclasts are involved in various pathologic conditions, such as osteoporosis, rheumatoid arthritis and tumor-induced bone disease, which are characterized by abnormal bone resorption, and the finding of RANKL has provided us a good therapeutic target for such pathologic conditions. 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17652963     DOI: 10.1159/000106484

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  26 in total

Review 1.  Tyrosine kinases as targets for the treatment of rheumatoid arthritis.

Authors:  Christina D'Aura Swanson; Ricardo T Paniagua; Tamsin M Lindstrom; William H Robinson
Journal:  Nat Rev Rheumatol       Date:  2009-06       Impact factor: 20.543

2.  Vertebral fractures affect functional status in postmenopausal rheumatoid arthritis patients.

Authors:  Yasunori Omata; Futoshi Hagiwara; Jinju Nishino; Ko Matsudaira; Yuho Kadono; Takuo Juji; Toshihito Mori; Hisanori Nakayama; Yuichi Nagase; Jun Hirose; Tetsuro Yasui; Takumi Matsumoto; Toshihiro Matsui; Shigeto Tohma; Sakae Tanaka
Journal:  J Bone Miner Metab       Date:  2013-12-21       Impact factor: 2.626

Review 3.  The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis.

Authors:  M Shawkat Razzaque
Journal:  Nat Rev Endocrinol       Date:  2009-11       Impact factor: 43.330

Review 4.  Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.

Authors:  Teun M Post; Serge C L M Cremers; Thomas Kerbusch; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 5.  FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?

Authors:  M Shawkat Razzaque
Journal:  Am J Physiol Renal Physiol       Date:  2008-11-19

6.  Induction of IL-8 in periodontal ligament cells by H(2)O (2).

Authors:  Yang-Sin Lee; Eun Jung Bak; Minyoung Kim; Wonse Park; Jeong Taeg Seo; Yun-Jung Yoo
Journal:  J Microbiol       Date:  2008-10-31       Impact factor: 3.422

7.  Effects of a GSK-3β inhibitor on the renal expression levels of RANK, RANKL and NF-κB in a rat model of diabetic nephropathy.

Authors:  Yi-Xia Zhou; Li-Xin Shi; Hua Yang; Yi-Guo Long; L U Meng; Li-Sa Lv; Yang Zhang; Huan Yao; Long Li; Yan-Ni Yu
Journal:  Exp Ther Med       Date:  2016-03-24       Impact factor: 2.447

8.  Loss of Cbl-b increases osteoclast bone-resorbing activity and induces osteopenia.

Authors:  Arata Nakajima; Archana Sanjay; Riccardo Chiusaroli; Naga Suresh Adapala; Lynn Neff; Cecile Itzsteink; William C Horne; Roland Baron
Journal:  J Bone Miner Res       Date:  2009-07       Impact factor: 6.741

9.  Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice.

Authors:  Hyunsoo Kim; Han Kyoung Choi; Ji Hye Shin; Kyung Hee Kim; Ji Young Huh; Seung Ah Lee; Chang-Yong Ko; Han-Sung Kim; Hong-In Shin; Hwa Jeong Lee; Daewon Jeong; Nacksung Kim; Yongwon Choi; Soo Young Lee
Journal:  J Clin Invest       Date:  2009-03-02       Impact factor: 14.808

10.  Discovery of a tetrazolyl β-carboline with in vitro and in vivo osteoprotective activity under estrogen-deficient conditions.

Authors:  Anirudha Karvande; Shahnawaz Khan; Irfan Khan; Deepti Singh; Vikram Khedgikar; Priyanka Kushwaha; Naseer Ahmad; Priyanka Kothari; Anupam Dhasmana; Ruchir Kant; Ritu Trivedi; Prem M S Chauhan
Journal:  Medchemcomm       Date:  2018-06-12       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.